Virios Therapeutics Files 8-K on Security Holder Vote
Ticker: DWTX · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1818844
| Field | Detail |
|---|---|
| Company | Virios Therapeutics, INC. (DWTX) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Virios Therapeutics held a shareholder vote on March 1st, details to follow.
AI Summary
Virios Therapeutics, Inc. filed an 8-K on March 6, 2024, reporting on a matter submitted to a vote of security holders as of March 1, 2024. The filing does not contain details about the specific vote or its outcome, only that it occurred.
Why It Matters
This filing indicates a formal process involving shareholder decisions, which could impact corporate governance and future strategic directions for Virios Therapeutics.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose material financial or operational changes.
Key Players & Entities
- Virios Therapeutics, Inc. (company) — Registrant
- March 1, 2024 (date) — Date of earliest event reported
- March 6, 2024 (date) — Date of report
FAQ
What was the specific matter submitted to a vote of Virios Therapeutics' security holders?
The filing does not specify the exact matter that was put to a vote of security holders.
When was the vote by security holders officially reported by Virios Therapeutics?
The vote by security holders was officially reported on March 6, 2024.
What is the earliest date associated with the event reported in this 8-K?
The earliest date associated with the event reported in this 8-K is March 1, 2024.
Does this 8-K filing provide the outcome of the security holder vote?
No, this 8-K filing does not provide the outcome of the security holder vote.
What is the primary purpose of this 8-K filing for Virios Therapeutics?
The primary purpose of this 8-K filing is to report on a submission of matters to a vote of security holders.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-03-06 16:30:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 VIRI Nasdaq Capital Market Check t
Filing Documents
- tmb-20240301x8k.htm (8-K) — 54KB
- 0001558370-24-002613.txt ( ) — 171KB
- tmb-20240301.xsd (EX-101.SCH) — 3KB
- tmb-20240301_lab.xml (EX-101.LAB) — 16KB
- tmb-20240301_pre.xml (EX-101.PRE) — 10KB
- tmb-20240301x8k_htm.xml (XML) — 5KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders On March 1, 2024, Virios Therapeutics, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). Present at the Special Meeting in person or by proxy were holders of 12,438,213 shares of common stock of the Company, representing 64.58% of the voting power of the shares of common stock of the Company as of the close of business on January 30, 2024, the record date for the Special Meeting, and constituting a quorum for the transaction of business. Each of Proposal 1 and Proposal 2, having received the votes required by the Company's bylaws and applicable law, were declared to be duly adopted at the meeting. The matters that were voted upon at the Special Meeting, and the number of votes cast for, withheld or against, as well as the number of abstentions and broker non-votes, as to each such matter are set forth below. 1. Approving the Reverse Stock Split Proposal. The approval of our reverse stock split was approved, with the following votes tabulated: For Against Abstain Broker Non-Vote 7,553,703 4,697,955 186,555 — 2. Approval of the Adjournment of the Special Meeting to a Later Date or Dates, if Necessary or Appropriate, to Solicit Additional Proxies if There Are Insufficient Votes to Adopt Proposal 1. The approval of approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1 was approved, with the following votes tabulated: For Against Abstain Broker Non-Vote 7,778,383 4,484,974 174,856 — 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIRIOS THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Senior Vice President of Finance, Corporate Secretary and Treasurer March 6, 2024 3